Novartis: Results of LIS2T Study Indicate that Neorala is Associated with Less Diabetes and Diarrhoea than Tacrolimus in Liver Transplantation
23. Juni 2003 01:38 ET
|
Novartis
BASEL, Switzerland, June 23, 2003 (PRIMEZONE) -- Novartis (Other OTC:NVSEF) today announced new study data found that liver transplant patients receiving Neoral (cyclosporin for microemulsion) and...
Novartis Releases Prexige; New Data Confirm That Prexige (lumiracoxib) is Effective in Relieving Symptoms of Osteoarthritis
20. Juni 2003 01:43 ET
|
Novartis
BASEL, Switzerland, June 20, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS)(Other OTC:NVSEF):
Data from key clinical Phase III studies presented for the first time at EULAR, the European League Against...
Novartis: New Study Shows Zelmac is Effective and Well Tolerated for Chronic Constipation
20. Mai 2003 01:43 ET
|
Novartis
BASEL, Switzerland, May 20, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS)(Other OTC:NVSEF):
New data from a large pivotal US trial demonstrates Zelmac(R) (tegaserod) was significantly more effective...
Novartis Closes Two Strategic Acquisitions in Pharmaceuticals
09. Mai 2003 01:46 ET
|
Novartis
BASEL, Switzerland, May 9, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF):
Incontinence treatment Enablex(R) purchased from Pfizer for up to USD 225 million
51% of Idenix acquired,...
`Coartem and Malaria' -- Novartis Launches International Education Program
24. April 2003 04:28 ET
|
Novartis
BASEL, SWITZERLAND, Switzerland, April 24, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF): launches international education program to ensure effective treatment with its fixed dose...
Novartis' First-Quarter Results 2003; Novartis Delivers Strong Growth in First Quarter Despite Weak Economic Environment
15. April 2003 01:49 ET
|
Novartis
BASEL, Switzerland, April 15, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF):
-- Group sales up 21% in USD (13% in local currencies);
Pharmaceuticals grows by 18% in USD (10% in...
Novartis Pre-Announcement -- First-Quarter Results 2003
14. April 2003 05:32 ET
|
Novartis
Basel, Switzerland, April 14, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF): Please note that we will publish our Group financial results for the first quarter of 2003 on Tuesday, April...
Novartis Wins Important Ruling Against GlaxoSmithKline and Continues to Market Generic Versions of Augmentin(R) in US
09. April 2003 02:00 ET
|
Novartis
BASEL, Switzerland, April 9, 2003 (PRIMEZONE) -- The Novartis Group (NYSE:NVS) (Other OTC:NVSEF) has won an important ruling in its legal dispute with GlaxoSmithKline (GSK) concerning AmoxC...
Novartis Signs Collaboration Agreement with Regeneron for Rheumatoid
28. März 2003 09:15 ET
|
Novartis
BASEL, Switzerland, March 28, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) (Other OTC:NVSEF):
- Partnership with Regeneron for IL-1 Cytokine Trap compound in phase II clinical development.
- Agreement...
Novartis to Acquire Enablex (Darifenacin), a New Incontinence Treatment for a Rapidly Expanding Population of Patients, from Pfizer
18. März 2003 10:33 ET
|
Novartis
BASEL, Switzerland, March 18, 2003 (PRIMEZONE) -- Novartis announced today that it will further strengthen its primary care product portfolio through the acquisition of Pfizer's M3 antagonist,...